ArticleJournal of virology2018
Adaptive Immune Responses following Senecavirus A Infection in Pigs.
Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 81 citations in OpenAlex.
- Article
- Determinants of Senecavirus A Pathogenesis: From Viral Genome to ANTXR1, Immunity, and Programmed Cell Death.Viruses · 2026Review
- Identification of a Conserved Linear Antigenic Determinant in the Senecavirus A VP1 Protein.Animals : an open access journal from MDPI · 2026Article
- Establishment and Application of a Novel Protein Microarray for Serological Detection and Differentiation of Senecavirus A.Transboundary and emerging diseases · 2026Article
- Indirect ELISA Using Multi-Antigenic Dominants of 3AB and 3C Recombinant Protein to Detect Antibodies Against Senecavirus A in Pigs.Veterinary sciences · 2025Article
- Phylogenetic Characterization and Seroprevalence ofAnimals : an open access journal from MDPI · 2025Article
- Comparison of Viral RNA Extraction Protocols for Senecavirus A and Classical Swine Fever Virus.Folia microbiologica · 2025Article
- A neutralizing nanobody-based liquid-phase blocking ELISA to assess the protective potency of Senecavirus A vaccine.Applied microbiology and biotechnology · 2025Article
- Characterization of T-cell immune responses againstFrontiers in immunology · 2025Article
- Identification of linear B-cell epitopes of Senecavirus A VP2 protein using monoclonal antibodies.Frontiers in microbiology · 2025Article
- Pathogenicity of the First Buffalo-origin Senecavirus A in Conventional Piglets and Buffaloes.Transboundary and emerging diseases · 2025Article
- ZFP36 Facilitates Senecavirus A (SVA) replication by inhibiting the production of type I interferon.Virus research · 2024Article
- The multiple roles of viral 3DVirulence · 2024Review
- Immunogenicity of an InactivatedVaccines · 2024Article
- Construction and characterization of a full-length infectious clone of an emerging senecavirus A strain.Archives of virology · 2024Article
- First assessment of weeks-to-negative processing fluids in breeding herds after a Senecavirus A outbreak.Porcine health management · 2024Article
- Development and characterization of a recombinant Senecavirus A expressing enhanced green fluorescent protein.Frontiers in microbiology · 2024Article
- Identification of a linear B-cell epitope on the "puff" loop of the Senecavirus A VP2 protein involved in receptor binding.Frontiers in microbiology · 2024Article
- Identification of Potential Novel B-Cell Epitopes of Capsid Protein VP2 in Senecavirus A.Microbiology spectrum · 2023Article
- Seneca Valley virus 3CFrontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Senecavirus A (SVA), an emerging picornavirus of swine, causes vesicular disease (VD) that is clinically indistinguishable from foot-and-mouth disease (FMD) in pigs. Many aspects of SVA interactions with the host and the host immune responses to infection, however, remain unknown. In the present study, humoral and cellular immune responses to SVA were evaluated following infection in pigs. We show that SVA infection elicited an early and robust virus-neutralizing (VN) antibody response, which coincided and was strongly correlated with VP2- and VP3-specific IgM responses. Notably, the neutralizing antibody (NA) responses paralleled the reduction of viremia and resolution of the disease. Analysis of the major porcine T-cell subsets revealed that during the acute/clinical phase of SVA infection (14 days postinfection [p.i.]), T-cell responses were characterized by an increased frequency of αβ T cells, especially CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.